(DOCM) DocMorris - Ratings and Ratios

DocMorris AG, formerly known as Zur Rose Group AG, operates as a leading e-commerce pharmacy and wholesale distributor of medical and pharmaceutical products across Switzerland and international markets. The company provides a comprehensive range of healthcare products, including prescription and over-the-counter (OTC) medications, consumer health items, beauty and personal care products, nutritional supplements, painkillers, and first aid supplies. Additionally, DocMorris offers professional health services, enhancing its position as a one-stop solution for healthcare needs. The company distributes its products through online mail-order pharmacies and directly to private individuals under its PromoFarma by DocMorris, TeleClinic, and DocMorris brands. Established in 1993 and headquartered in Frauenfeld, Switzerland, DocMorris has grown significantly, adapting to the evolving digital healthcare landscape while maintaining a strong focus on customer convenience and accessibility.

As of May 2023, the company completed its rebranding from Zur Rose Group AG to DocMorris AG, reflecting its strategic commitment to expanding its digital healthcare services and strengthening its market presence. DocMorris AG continues to leverage its e-commerce platform to deliver a seamless user experience, offering fast delivery options and a wide product range tailored to diverse customer needs. The companys wholesale business further solidifies its position as a key player in the pharmaceutical supply chain, catering to both online pharmacies and private customers.

Ticker Symbol: DOCM, Exchange: SW, Type: Common stock, Country Origin: Switzerland, GICS Sub Industry: Drug Retail.

Based on the provided data, the 3-month forecast for DocMorris AG (SW:DOCM) indicates a bearish outlook. The stock is currently trading below its 20-day and 50-day moving averages, with the 200-day moving average significantly higher at 37.53, suggesting downward momentum. The average true range (ATR) of 1.18 reflects moderate volatility, which may decrease in the coming months. The negative price-to-earnings ratio (P/E) and forward P/E, along with a return on equity (RoE) of -36.50%, signal financial challenges and poor profitability. These factors, combined with a price-to-book (P/B) ratio of 0.62 and a price-to-sales (P/S) ratio of 0.24, suggest that the stock may face continued downward pressure. The low trading volume of 119,861 shares over the past 20 days further indicates limited investor interest. Overall, the stock is expected to remain under pressure, with potential stabilization at lower levels.